公开(公告)号：JP2011172574A

公开(公告)日：2011-09-08

申请号：JP2011059978

申请日：2011-03-18

Applicant: Stichting Katholieke Univ Univ Medical Centre Nijmegen ,  スティヘイティング カソリケ ユニフェルシテイト、ユニバーシティ メディカル センター ナイメーヘン

Inventor： SCHALKEN JACK A ,  VERHAEGH GERALD ,  HESSELS DAPHNE ,  SMIT FRANK

IPC: C12Q1/68 ,  C12N15/09

CPC classification number: C12Q1/6886 ,  C12Q2600/158

Abstract: PROBLEM TO BE SOLVED: To provide a method for diagnosing prostate cancer of a patient by detecting a PCA3 sequence, for example, a PCA3 RNA in a sample from the patient to be or not to be specifically associated with prostate cancer, and an in vitro method for detecting kidney cells or bladder cells from a non-prostate sample derived from the urinary tract.
SOLUTION: The method for detecting the presence of kidney cells or bladder cells in the sample includes isolating the RNA from the non-prostate sample derived from the objective organism, amplifying PCA3 nucleic acid contained in the RNA using a primer and detecting the amplified nucleic acid including intron 3 of PCA3 or a complimentary chain thereof in the collected amplified product.
COPYRIGHT: (C)2011,JPO&INPIT

Abstract translation: 要解决的问题：提供一种通过检测PCA3序列来诊断患者的前列腺癌的方法，例如来自患者的样品中的PCA3 RNA将与前列腺癌特异性相关，以及 用于从源自泌尿道的非前列腺样品检测肾细胞或膀胱细胞的体外方法。 解决方案：用于检测样品中肾细胞或膀胱细胞存在的方法包括从来自目标生物体的非前列腺样品中分离RNA，使用引物扩增RNA中所含的PCA3核酸，并检测 在收集的扩增产物中扩增的核酸包括PCA3的内含子3或其互补链。 版权所有（C）2011，JPO＆INPIT

公开(公告)号：WO2006066965A3

公开(公告)日：2006-10-26

申请号：PCT/EP2005014021

申请日：2005-12-23

Applicant: STICHTING KATHOLIEKE UNIV ,  HESSELS DAPHNE ,  VERHAEGH GERALD ,  SCHALKEN JACK A ,  WITJES ALFRED J

Inventor： HESSELS DAPHNE ,  VERHAEGH GERALD ,  SCHALKEN JACK A ,  WITJES ALFRED J

IPC: C12Q1/68

CPC classification number: C12Q1/6886 ,  C12Q2600/112 ,  C12Q2600/118 ,  C12Q2600/158 ,  C12Q2600/16 ,  G01N33/57434 ,  G01N2333/96455

Abstract: Described herein are methods and kits for prognosis of prostate cancer in a subject. The methods comprises: (a) determining the ratio of PCA3 and PSA expression in a urine sample and (b) correlating the value of the PCA3/PSA ratio with the aggressiveness and mortality risk of prostate cancer in the subject. Kits for prognosing prostate cancer are also described. More particularly, the present invention features a method for prognosing prostate cancer in a biological sample of a patient comprising: assessing the amount of a prostate cancer specific PCA3 mRNA and the amount of PSA in the biological sample; determining a ratio value of this amount of prostate cancer specific PCA3 mRNA over the amount of PSA; comparing the ratio value to at least one predetermined cut-off value, wherein a ratio value above the predetermined cut-off value is indicative of a higher risk of mortality of prostate cancer as compared to a ratio value below the predetermined cut-off value.

Abstract translation: 本文描述了受试者中前列腺癌预后的方法和试剂盒。 方法包括：（a）确定尿液样品中PCA3和PSA表达的比例，以及（b）将PCA3 / PSA比值与患者前列腺癌的侵袭性和死亡风险相关联。 还描述了用于预测前列腺癌的试剂盒。 更具体地，本发明的特征在于一种用于在患者的生物样品中预测前列腺癌的方法，包括：评估前列腺癌特异性PCA3 mRNA的量和生物样品中的PSA量; 确定该量的前列腺癌特异性PCA3 mRNA与PSA量的比值; 将所述比值与至少一个预定截止值进行比较，其中高于所述预定临界值的比率值指示与低于所述预定截止值的比率值相比较，前列腺癌的死亡风险更高。

公开(公告)号：WO2005003387A3

公开(公告)日：2005-03-31

申请号：PCT/EP2004007124

申请日：2004-06-30

Applicant: STICHTING KATHOLIEKE UNIV ,  SCHALKEN JACK A ,  VERHAEGH GERALD ,  HESSELS DAPHNE ,  SMIT FRANK

Inventor： SCHALKEN JACK A ,  VERHAEGH GERALD ,  HESSELS DAPHNE ,  SMIT FRANK

IPC: C12Q1/68

CPC classification number: C12Q1/6886 ,  C12Q2600/158

Abstract: The present invention relates, in general, to prostate cancer. More specifically, the present invention relates to a method to diagnose prostate cancer in a, patient by detecting a PCA3 sequence, and more particularly a PCA3 RNA, the PCA3 sequence detected in a sample from the patient being specifically associated with prostate cancer. In a particular embodiment the method and kit enables an amplification of a PCA3 RNA through an exon-exon junction of a spliced PCA3 mRNA. The invention also related to methods and kits to detect such an amplified PCA3 RNA, using a probe which spans the amplified exonexon junction. The invention also relates to kits containing nucleic acid primers and kits containing nucleic acid primers and nucleic acid probes to diagnose, assess, or prognose a human afflicted with prostate cancer. In particular the methods and kits are designed to detect a PCA3 RNA which lacks one intron or more, and in particular case is intron-less.

Abstract translation: 本发明一般涉及前列腺癌。 更具体地，本发明涉及通过检测PCA3序列，特别是PCA3 RNA来诊断患者中的前列腺癌的方法，所述PCA3 RNA是来自与前列腺癌特异性相关的患者的样品中检测到的PCA3序列。 在一个具体实施方案中，该方法和试剂盒能够通过拼接的PCA3 mRNA的外显子 - 外显子连接扩增PCA3 RNA。 本发明还涉及使用跨越扩增的外显子结的探针来检测这种扩增的PCA3 RNA的方法和试剂盒。 本发明还涉及含有核酸引物和试剂盒的试剂盒，所述试剂盒包含用于诊断，评估或预测患有前列腺癌的人的核酸引物和核酸探针。 特别地，方法和试剂盒被设计用于检测缺乏一个或多个内含子的PCA3RNA，特别是内含子。

公开(公告)号：CA2530646C

公开(公告)日：2015-11-03

申请号：CA2530646

申请日：2004-06-30

Applicant: STICHTING KATHOLIEKE UNIV

Inventor： SCHALKEN JACK A ,  VERHAEGH GERALD ,  HESSELS DAPHNE ,  SMIT FRANK

IPC: C12Q1/68

Abstract: The present invention relates, in general, to prostate cancer. More specifically, the present invention relates to a method to diagnose prostate cancer in a, patient by detecting a PCA3 sequence, and more particularly a PCA3 RNA, the PCA3 sequence detected in a sample from the patient being specifically associated with prostate cancer. In a particular embodiment the method and kit enables an amplification of a PCA3 RNA through an exon-exon junction of a spliced PCA3 mRNA. The invention also related to methods and kits to detect such an amplified PCA3 RNA, using a probe which spans the amplified exonexon junction. The invention also relates to kits containing nucleic acid primers and kits containing nucleic acid primers and nucleic acid probes to diagnose, assess, or prognose a human afflicted with prostate cancer. In particular the methods and kits are designed to detect a PCA3 RNA which lacks one intron or more, and in particular case is intron-less.

公开(公告)号：CA2594125C

公开(公告)日：2016-06-14

申请号：CA2594125

申请日：2005-12-23

Applicant: STICHTING KATHOLIEKE UNIV THE UNIV MEDICAL CENTRE NIJMEGEN

Inventor： HESSELS DAPHNE ,  VERHAEGH GERALD ,  SCHALKEN JACK A ,  WITJES J ALFRED

IPC: C12Q1/68

Abstract: Described herein are methods and kits for prognosis of prostate cancer in a subject. The methods comprises: (a) determining the ratio of PCA3 and PSA expression in a urine sample and (b) correlating the value of the PCA3/PSA ratio with the aggressiveness and mortality risk of prostate cancer in the subject. Kits for prognosing prostate cancer are also described. More particularly, the present invention features a method for prognosing prostate cancer in a biological sample of a patient comprising: assessing the amount of a prostate cancer specific PCA3 mRNA and the amount of PSA in the biological sample; determining a ratio value of this amount of prostate cancer specific PCA3 mRNA over the amount of PSA; comparing the ratio value to at least one predetermined cut-off value, wherein a ratio value above the predetermined cut-off value is indicative of a higher risk of mortality of prostate cancer as compared to a ratio value below the predetermined cut-off value.

公开(公告)号：DE602005019294D1

公开(公告)日：2010-03-25

申请号：DE602005019294

申请日：2005-12-23

Applicant: STICHTING KATHOLIEKE UNIV

Inventor： HESSELS DAPHNE ,  VERHAEGH GERALD ,  SCHALKEN JACK A ,  WITJES J ALFRED

IPC: C12Q1/68

公开(公告)号：CA2594125A1

公开(公告)日：2006-06-29

申请号：CA2594125

申请日：2005-12-23

Applicant: STICHTING KATHOLIEKE UNIV

Inventor： HESSELS DAPHNE ,  SCHALKEN JACK A ,  VERHAEGH GERALD ,  WITJES J ALFRED

IPC: C12Q1/68

公开(公告)号：CA2530646A1

公开(公告)日：2005-01-13

申请号：CA2530646

申请日：2004-06-30

Applicant: STICHTING KATHOLIEKE UNIV

Inventor： SCHALKEN JACK A ,  SMIT FRANK ,  VERHAEGH GERALD ,  HESSELS DAPHNE

IPC: C12Q1/68

Abstract: The present invention relates, in general, to prostate cancer. More specifically, the present invention relates to a method to diagnose prostate cancer in a, patient by detecting a PCA3 sequence, and more particularly a PCA3 RNA, the PCA3 sequence detected in a sample from the patient being specifically associated with prostate cancer. In a particular embodiment the method and kit enables an amplification of a PCA3 RNA through an exon-exon junction of a spliced PCA3 mRNA. The invention also related to methods and kits to detect such an amplified PCA3 RNA, using a probe which spans the amplified exonexon junction. The invention also relates to kits containing nucleic acid primers and kits containing nucleic acid primers and nucleic ac id probes to diagnose, assess, or prognose a human afflicted with prostate cancer. In particular the methods and kits are designed to detect a PCA3 RNA which lacks one intron or more, and in particular case is intron-less.

公开(公告)号：ES2546193T3

公开(公告)日：2015-09-21

申请号：ES10152258

申请日：2005-12-23

Applicant: STICHTING KATHOLIEKE UNIV

Inventor： HESSELS DAPHNE ,  VERHAEGH GERALD ,  SCHALKEN JACK A ,  WITJES ALFRED J

IPC: C12Q1/68

Abstract: Procedimiento para pronosticar el cáncer de próstata en una muestra de orina de un paciente, que comprende: (a) valorar la cantidad de ARNm de PCA3 específico de cáncer de próstata y la cantidad de un marcador específico de próstata en dicha muestra de orina; (b) determinar un valor de la razón de dicha cantidad de dicho ARNm de PCA3 específico de cáncer de próstata en función de dicha cantidad de marcador específico de próstata; y (c) comparar dicho valor de la razón con al menos un valor umbral predeterminado, en donde un valor de la razón superior a dicho valor umbral predeterminado es indicativo de un cáncer de próstata más agresivo en comparación con un valor de la razón inferior a dicho valor umbral predeterminado.

公开(公告)号：HK1148315A1

公开(公告)日：2011-09-02

申请号：HK11102244

申请日：2011-03-07

Applicant: STICHTING KATHOLIEKE UNIV

Inventor： HESSELS DAPHNE ,  VERHAEGH GERALD ,  SCHALKEN JACK A ,  WITJES ALFRED J

IPC: C12Q20060101